Drug Trial Radar · NCT07005154
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Aug 19, 2025
Primary completion
May 31, 2032
Study completion May 31, 2032
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy. ASP5541 is a different form of abiraterone acetate. It is given as an injection into the muscle. In this study, ASP5541 will be given to men with advanced prostate cancer, both with and without prednisone/prednisolone. This study will check the safety of ASP5541 and compare how well ASP5541 works in men with advanced prostate cancer compared to abiraterone acetate. The main aims of the study are: * To check how well ASP5541 with prednisone/prednisolone works compared to AA with prednisone/prednisolone in men with advanced prostate cancer who haven't previously been treated with an ARPI. * To check the safety of ASP5541 given by itself in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check how well ASP5541 given by itself works compared to AA with prednisone/prednisolone in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check the safety of ASP5541 with prednisone/prednisolone in Japanese men with advanced prostate cancer. Adult men with a certain type of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types are: * Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow. * Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low. In this study there will be 3 treatment groups: * In Group 1, men with mCRPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 and prednisone/prednisolone or be given abiraterone acetate and prednisone/prednisolone. * In Group 2, men with mHSPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 by itself or be given abiraterone acetate with prednisone/prednisolone. * In Group 3, Japanese men with mCRPC or mHSPC who may or may not have previously been treated with an androgen receptor pathway inhibitor will be given ASP5541 with prednisone/prednisolone. ASP5541 will be given as an injection into a muscle every 12 weeks. Men with mCRPC will take prednisone/prednisolone twice daily and men with mHSPC will take prednisone/prednisolone once daily. Abiraterone acetate will be given as tablets to be taken once daily. All groups will also receive the standard of care treatment, such as androgen deprivation therapy. The men in the study will visit their clinic regularly during and after treatment for health checks, including checking for any medical problems. Some men (Group 2) will check their blood pressure weekly at home. On some visits they will also have scans to check for any changes in their cancer. The number of visits and type of safety checks done at each visit will depend on the health of each person and when they completed their treatment.
Conditions
- Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Hormone Sensitive Prostate Cancer
Interventions
ASP5541Drug
Intramuscular Injection
PrednisoneDrug
Oral
PrednisoloneDrug
Oral
abiraterone acetateDrug
Oral
Adrenocorticotropic hormoneDrug
Intramuscular or intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of androgen receptor pathway inhibitor (ARPI) -naïve metastatic castration-resistant prostate cancer (mCRPC) participants with Prostate Specific Antigen (PSA) decline ≥ 90% (Cohort 1)Time frame: Up to 37 months
- Rate of no mineralocorticoid toxicity (Cohort 2 Group A, Safety run-in)Time frame: Up to 37 months
- Proportion of metastatic hormone-sensitive prostate cancer (mHSPC) participants with prostate-specific antigen (PSA) ≤ 0.2 ng/mL (Cohort 2)Time frame: At 8 months
- Dose-limiting toxicities (DLTs) (Cohort 3)Time frame: Up to Day 28
- Number of participants with Adverse Events (AEs) (Cohort 3)Time frame: Up to 39 months
- Number of Participants With Serious Adverse Events (SAEs) (Cohort 3)Time frame: Up to 39 months
- Number of participants with laboratory value abnormalities and/or AEs (Cohort 3)Time frame: Up to 37 months
- Number of participants with electrocardiogram (ECG) abnormalities and/or AEs (Cohort 3)Time frame: Up to 36 months
- Number of participants with vital sign abnormalities and/or AEs (Cohort 3)Time frame: Up to 37 months
- Number of participants with physical exam abnormalities and/or AEs (Cohort 3)Time frame: Up to 36 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status (Cohort 3)Time frame: Up to 36 months
Locations
54 sites in 12 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama · Recruiting
Sharp HealthCare - Sharp Memorial Hospital
San Diego, California · Recruiting
H. Lee Moffitt Cancer Center
Tampa, Florida · Recruiting
Associated Urological Specialists
Chicago Ridge, Illinois · Recruiting
NorthShore University HealthSystem
Evanston, Illinois · Recruiting
Ochsner Health - Ochsner Medical Center - New Orleans
New Orleans, Louisiana · Recruiting
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico · Recruiting
Solaris Health - The Urology Group
Cincinnati, Ohio · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Tennessee Oncology Nashville
Nashville, Tennessee · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
UW Health Carbone Cancer Center
Madison, Wisconsin · Recruiting
Huai'an First People's Hospital
Huaian, China · Recruiting
Renji Hospital Shanghai Jiaotong Univ School of Medicine
Shanghai, China · Recruiting
Subei People's Hospital
Yangzhou, Jiangsu, China · Recruiting
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Site FR33003
Bordeaux, France · Recruiting
Site FR33009
Le Mans, France · Recruiting
Site FR33008
Lille, France · Recruiting
Site FR33006
Paris, France · Recruiting
Site FR33004
Strasbourg, France · Recruiting
Site DE49001
Heinsberg, Germany · Recruiting
Site DE49004
Nürtingen, Baden-Wurttemberg, Germany · Recruiting
Site IT39004
Milan, Italy · Recruiting
Site IT39006
Milan, Italy · Recruiting
Site IT39005
Roma, Italy · Recruiting
Site IT39003
Trento, Italy · Recruiting
Harasanshin Hospital
Fukuoka, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan · Recruiting
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto, Tokyo, Japan · Recruiting
Site PL48003
Gdansk, Poland · Recruiting
Site PL48007
Gliwice, Poland · Recruiting
Site PL48005
Mysłowice, Poland · Recruiting
Site PL48008
Otwock, Poland · Recruiting
PanOncology Trials
San Juan, Puerto Rico · Recruiting
Site KR82006
Daegu, South Korea · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.